systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075082X.2020.2.200236systhiper-627Research ArticleОБЗОРREVIEWПОАК: технологии, меняющие жизньDOACs: life-changing technologiesПанченкоЕ. П.PanchenkoE. P.info@eco-vector.comШахновичР. М.ShakhnovichR. M.info@eco-vector.comАгеевФ. Т.AgeevF/. T.info@eco-vector.comКомаровА. Л.KomarovA. L.info@eco-vector.comФГБУ «НМИЦ кардиологии» Минздрава РоссииРоссияFSBI "National Medical Research Center of Cardiology" of the Ministry of Health of RussiaRussian FederationИнститута клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава РоссииРоссияInstitute of Clinical Cardiology. A.L. Myasnikov Federal State Budgetary Institution "National Medical Research Center of Cardiology" of the Ministry of Health of RussiaRussian FederationКлиническая кардиология им. А.Л. МясникРоссияClinical Cardiology. A.L. ButcherRussian Federation2020231220221726975Copyright © Панченко Е.П., Шахнович Р.М., Агеев Ф.Т., Комаров А.Л., 20222022Панченко Е.П., Шахнович Р.М., Агеев Ф.Т., Комаров А.Л.Panchenko E.P., Shakhnovich R.M., Ageev F.T., Komarov A.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/627

VIII Евразийский конгресс кардиологов. Обзор симпозиумов. ПОАК: технологии, меняющие жизнь. Системные гипертензии.

VIII Eurasian Congress of Cardiology. Overview of symposiums. DOACs: life-changing technologies. Systemic Hypertension

ReferencesHeit et al. 2000.Heit et al. 2000.Timp et al. 2013Timp et al. 2013Khorana AA et al. J Thromb and Haemost 2007Khorana AA et al. J Thromb and Haemost 2007Bassand JP, Accetta G, Camm AJ et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016; 37 (38): 2882-9Bassand JP, Accetta G, Camm AJ et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016; 37 (38): 2882-9Американское ретроспективное исследование - тромбогенность раковАмериканское ретроспективное исследование - тромбогенность раковМетаанализ низкомолекулярных гепаринов против варфарина. 2017Метаанализ низкомолекулярных гепаринов против варфарина. 2017Рекомендации ESC/ERS. 2019Рекомендации ESC/ERS. 2019Schulman et al. Thromb Haemost 2015; 114: 150-7Schulman et al. Thromb Haemost 2015; 114: 150-7Prins M et al. Lancet Haematol 2014; 1: e37-46Prins M et al. Lancet Haematol 2014; 1: e37-46Agnelli G et al. DOI: 10.1111/JTH13153Agnelli G et al. DOI: 10.1111/JTH13153Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New Eng J Med 2017Raskob GE, van Es N, Verhamme P et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. New Eng J Med 2017Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36: 2017-23Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36: 2017-23McBane RD, Wysokinski WE, Le-Rademacher J et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism, the ADAM VTE trial. DOI: 10.1111/JTH14662McBane RD, Wysokinski WE, Le-Rademacher J et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism, the ADAM VTE trial. DOI: 10.1111/JTH14662Метаанализ исследований апиксабана в условиях реальной клинической практики. 2019Метаанализ исследований апиксабана в условиях реальной клинической практики. 2019Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. New Eng J Med 2020; 382 (17): 1599-607Agnelli G, Becattini C, Meyer G et al. Apixaban for the treatment of venous thromboembolism associated with cancer. New Eng J Med 2020; 382 (17): 1599-607Рекомендации ESC по лечению пациентов с ОКСбпST. Рос. кардиологический журн. 2016; 131 (3)Рекомендации ESC по лечению пациентов с ОКСбпST. Рос. кардиологический журн. 2016; 131 (3)Объединенные данные исследований III фазы по сравнению ПОАКсварфарином в подгруппе пожилыхОбъединенные данные исследований III фазы по сравнению ПОАКсварфарином в подгруппе пожилыхИсследование AUGUSTUSИсследование AUGUSTUSHalvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35:1864-72Halvorsen S, Atar D, Yang H et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35:1864-72Исследование AVERROESИсследование AVERROESИсследование ENGAGEИсследование ENGAGEEikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123 (21): 2363-72Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123 (21): 2363-72Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014; 130 (2): 138-46Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation 2014; 130 (2): 138-46Li X. Крупное исследование апиксабана против варфарина в условиях реальной практикиLi X. Крупное исследование апиксабана против варфарина в условиях реальной практикиDiener HC, Aisenberg J, Ansell J et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017; 38 (12): 860-8Diener HC, Aisenberg J, Ansell J et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017; 38 (12): 860-8Субанализ ARISTOTLE при хронической почечной недостаточностиСубанализ ARISTOTLE при хронической почечной недостаточностиСубанализ RE-LY при хронической почечной недостаточностиСубанализ RE-LY при хронической почечной недостаточностиСубанализ ROCKET AF при хронической почечной недостаточностиСубанализ ROCKET AF при хронической почечной недостаточностиСубанализ ARISTOTLE при сахарном диабетеСубанализ ARISTOTLE при сахарном диабетеСубанализ RE-LY при сахарном диабетеСубанализ RE-LY при сахарном диабетеСубанализ ROCKET AF при сахарном диабетеСубанализ ROCKET AF при сахарном диабетеЕвразийские клинические рекомендации по диагностике и лечению ОКСсподъемом сегмента ST. 2019Евразийские клинические рекомендации по диагностике и лечению ОКСсподъемом сегмента ST. 2019Рекомендации ESC/EACTS по реваскуляризации миокарда. Eur Heart J 2019; 49: 87-165Рекомендации ESC/EACTS по реваскуляризации миокарда. Eur Heart J 2019; 49: 87-165Практическое руководство Европейской ассоциации сердечного ритма (EHRA) по использованию оральных антикоагулянтов - не-АВКупациентов с ФП. 2018Практическое руководство Европейской ассоциации сердечного ритма (EHRA) по использованию оральных антикоагулянтов - не-АВКупациентов с ФП. 2018Исследование ARISTOTLEИсследование ARISTOTLEРекомендации ESC/EACTS по лечению ФП. 2016Рекомендации ESC/EACTS по лечению ФП. 2016Мареев В.Ю., Фомин И.В., Агеев Ф.Т. Клинические рекомендациях ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (S6)Мареев В.Ю., Фомин И.В., Агеев Ф.Т. Клинические рекомендациях ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018; 58 (S6)Connolly SJ et al. N Eng J Med 2009; 361: 1139-51Connolly SJ et al. N Eng J Med 2009; 361: 1139-51Pokorney SD, Piccini JP, Stevens SR et al. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Association 2016; 5 (3): e002197Pokorney SD, Piccini JP, Stevens SR et al. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Association 2016; 5 (3): e002197Diener HC, Aisenberg J, Ansell J et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017; 38 (12): 860-8Diener HC, Aisenberg J, Ansell J et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017; 38 (12): 860-8Wehling M, Collins R, Gil VM et al. Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016). Drugs Aging 2017; 34 (7): 499-507Wehling M, Collins R, Gil VM et al. Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people: results of an evidence-based review and international consensus validation process (OAC-FORTA 2016). Drugs Aging 2017; 34 (7): 499-507Исследование ARISTOPHANESИсследование ARISTOPHANESAmin A, Reeves ABG, Li X et al. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PloS ONE 2019; 14 (3): e0213614Amin A, Reeves ABG, Li X et al. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. PloS ONE 2019; 14 (3): e0213614Fralick M, Colacci M, Schneeweiss S et al. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: A cohort study. Ann Int Med 2020; 172 (7): 463-73Fralick M, Colacci M, Schneeweiss S et al. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: A cohort study. Ann Int Med 2020; 172 (7): 463-73Поляков Д.С., Фомин И.В, Вилкулова Ф.Ю. и др. Эпидемиологическая программа ЭПОХА-ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА-Д-ХСН). Сердечная недостаточность. 2016; 17 (6): 299-305Поляков Д.С., Фомин И.В, Вилкулова Ф.Ю. и др. Эпидемиологическая программа ЭПОХА-ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА-Д-ХСН). Сердечная недостаточность. 2016; 17 (6): 299-305Pokorney SD, Piccini JP, Stevens SR et al. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Association 2016; 5 (3): e002197Pokorney SD, Piccini JP, Stevens SR et al. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. J Am Heart Association 2016; 5 (3): e002197Bassand JP, Accetta G, Camm AJ et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016; 37 (38): 2882-9Bassand JP, Accetta G, Camm AJ et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016; 37 (38): 2882-9Hylek EM, Held C, Alexander JH et al. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. J Am College Cardiol 2014; 63 (20): 2141-7Hylek EM, Held C, Alexander JH et al. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. J Am College Cardiol 2014; 63 (20): 2141-7Рекомендации EHRA. 2018Рекомендации EHRA. 2018Stanifer JW, Pokorney SD, Chertow GM et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020; 141 (17): 1384-92Stanifer JW, Pokorney SD, Chertow GM et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020; 141 (17): 1384-92Stacy ZA, Richter SK. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations. Ther Adv Cardiovasc Dis 2018; 12 (9): 247-62Stacy ZA, Richter SK. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations. Ther Adv Cardiovasc Dis 2018; 12 (9): 247-62Deitelzwei S, Keshishian A, Li X et al. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. J Am Geriatr Soc 2019. DOI: 10.1111/jgs.15956Deitelzwei S, Keshishian A, Li X et al. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. J Am Geriatr Soc 2019. DOI: 10.1111/jgs.15956Sehested TSG, Carlson N, Hansen PW et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J 2019. DOI: 10.1093/eurheartj/ehz104Sehested TSG, Carlson N, Hansen PW et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J 2019. DOI: 10.1093/eurheartj/ehz104Garcia DA, Fisher DA, Mulder H et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J 2019. DOI: 10.1016/j.ahj.2019.10.013Garcia DA, Fisher DA, Mulder H et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J 2019. DOI: 10.1016/j.ahj.2019.10.013Ray WA, Chung CP, Murray KT et al. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA 2018; 320 (21): 2221. DOI: 10.1001/jama.2018.17242Ray WA, Chung CP, Murray KT et al. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA 2018; 320 (21): 2221. DOI: 10.1001/jama.2018.17242Bahit MC, Lopes RD, Wojdyla DM et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 2016; 103 (8): 623-8Bahit MC, Lopes RD, Wojdyla DM et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 2016; 103 (8): 623-8Lip GYH, Keshishian A, Li X et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018; 49 (12): 2933-44. DOI: 10.1161/strokeaha.118.020232Lip GYH, Keshishian A, Li X et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 2018; 49 (12): 2933-44. DOI: 10.1161/strokeaha.118.020232

The authors declare that there are no conflicts of interest present.